Loading...

Nihon Kohden Corporation

NHNKYPNK
Healthcare
Medical - Devices
$11.20
$0.33(3.04%)

Nihon Kohden Corporation (NHNKY) Financial Performance & Income Statement Overview

View comprehensive annual and quarterly summaries for Nihon Kohden Corporation (NHNKY), featuring income statements, balance sheets, and cash flow data.

Revenue Growth
1.55%
1.55%
Operating Income Growth
5.73%
5.73%
Net Income Growth
-17.20%
17.20%
Operating Cash Flow Growth
-2.06%
2.06%
Operating Margin
9.19%
9.19%
Gross Margin
51.97%
51.97%
Net Profit Margin
6.25%
6.25%
ROE
7.91%
7.91%
ROIC
11.14%
11.14%

Nihon Kohden Corporation (NHNKY) Income Statement & Financial Overview

Analyze Nihon Kohden Corporation’s NHNKY earnings with segmented quarterly and yearly financial statement figures.

MetricQ4 2024Q3 2024Q2 2024Q1 2024
Revenue$66.95B$55.69B$56.56B$46.23B
Cost of Revenue$32.22B$25.17B$26.51B$24.37B
Gross Profit$34.73B$30.52B$30.05B$21.86B
Gross Profit Ratio$0.52$0.55$0.53$0.47
R&D Expenses$0.00$0.00$1.58B$1.60B
SG&A Expenses$24.95B$24.70B$22.10B$21.50B
Operating Expenses$24.95B$24.70B$23.69B$23.11B
Total Costs & Expenses$57.17B$49.87B$50.20B$47.48B
Interest Income$181.00M$90.00M$100.00M$57.00M
Interest Expense$93.00M$35.00M$8.00M$8.00M
Depreciation & Amortization$1.23B$1.03B$992.00M$933.00M
EBITDA$9.62B$6.85B$7.36B-$315.00M
EBITDA Ratio$0.14$0.12$0.13-$0.007
Operating Income$9.78B$5.82B$6.36B-$1.25B
Operating Income Ratio$0.15$0.10$0.11-$0.03
Other Income/Expenses (Net)-$1.48B$5.54B-$6.12B$2.92B
Income Before Tax$8.30B$11.37B$240.00M$1.67B
Income Before Tax Ratio$0.12$0.20$0.004$0.04
Income Tax Expense$2.33B$3.69B$543.00M$902.00M
Net Income$5.96B$7.67B-$303.00M$766.00M
Net Income Ratio$0.09$0.14-$0.005$0.02
EPS$36.38$46.36-$1.81$4.57
Diluted EPS$36.38$46.36-$1.81$4.57
Weighted Avg Shares Outstanding$163.83M$165.53M$167.27M$167.79M
Weighted Avg Shares Outstanding (Diluted)$163.83M$165.53M$167.27M$167.79M

Financial performance has remained strong, with revenue growing from $46.23B in Q1 2024 to $66.95B in Q4 2024. Gross profit continued to perform well, with margins at 52% in the latest quarter. Operating income reached $9.78B in Q4 2024, holding a steady 15% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $9.62B. Net income dropped to $5.96B, keeping EPS at $36.38. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;